Regarding the PCSK9 inhibitors, RCTs have clearly shown that alirocumab or evolocumab administration does not lead to new-onset diabetes or aggravate pre-existent type 2 diabetes mellitus (36). This evidence concerns the gene PCSK9 and diabetes mellitus.